Investigational Drug Information for Iniparib
What is the development status for investigational drug Iniparib?
Iniparib is an investigational drug.
There have been 21 clinical trials for Iniparib.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2009.
The most common disease conditions in clinical trials are Breast Neoplasms, Triple Negative Breast Neoplasms, and Neoplasms. The leading clinical trial sponsors are Sanofi, BiPar Sciences, and Gynecologic Oncology Group.
Summary for Iniparib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 2,042 |
| WIPO Patent Applications | 678 |
| Japanese Patent Applications | 211 |
| Clinical Trial Progress | Phase 3 (2009-07-01) |
| Vendors | 72 |
Recent Clinical Trials for Iniparib
| Title | Sponsor | Phase |
|---|---|---|
| Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. | Spanish Breast Cancer Research Group | Phase 1/Phase 2 |
| Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. | Cantargia AB | Phase 1/Phase 2 |
| Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial | Sanofi | Phase 3 |
Clinical Trial Summary for Iniparib
Top disease conditions for Iniparib
Top clinical trial sponsors for Iniparib
US Patents for Iniparib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Iniparib Development Update, Patent Status, and Market Projection
Iniparib, formerly BSI-201, is a discontinued investigational small-molecule cancer drug. Sanofi stopped development after a Phase III trial failed to confirm the efficacy reported in an earlier Phase II study. Iniparib was never approved by the FDA, never received an Orange Book listing, and has no established commercial market. The base-case 2024-2030 revenue projection is effectively zero unless a new sponsor restarts development with a new clinical strategy.
What is the current development status of iniparib?
Iniparib development is clinically inactive.
BiPar Sciences developed iniparib as a treatment for metastatic triple-negative breast cancer. Sanofi acquired BiPar in 2009 in a transaction valued at up to approximately $500 million, including milestone payments. Sanofi later expanded development into other cancers, including ovarian cancer and squamous non-small-cell lung cancer.
The program lost commercial viability after a large Phase III trial failed to reproduce the Phase II results. Sanofi discontinued further development for metastatic triple-negative breast cancer in 2011 and subsequently ended broader iniparib development.
| Development milestone | Date | Status |
|---|---|---|
| BiPar Sciences advances BSI-201 | 2000s | Investigational |
| Sanofi acquires BiPar Sciences | 2009 | Upfront and contingent consideration reported at up to about $500 million |
| Phase II metastatic triple-negative breast cancer study published | 2010 | Positive result |
| Phase III metastatic triple-negative breast cancer study | 2010-2011 | Failed primary efficacy assessment |
| Sanofi ends breast-cancer development | 2011 | Discontinued |
| Broader oncology development | 2011-2013 | No confirmed registration path |
| FDA approval | None | No approved product |
The drug is not an active late-stage pipeline asset for Sanofi. Public development activity has not established a credible path toward regulatory filing.
Why did iniparib fail in Phase III?
The Phase III trial did not confirm a clinically meaningful overall benefit.
The earlier Phase II study randomized 123 patients with metastatic triple-negative breast cancer to gemcitabine and carboplatin with or without iniparib. The iniparib arm reported longer median progression-free survival and overall survival:
| Outcome | Chemotherapy plus iniparib | Chemotherapy alone |
|---|---|---|
| Median progression-free survival | 5.9 months | 3.6 months |
| Median overall survival | 12.3 months | 7.7 months |
| Objective response rate | 52% | 32% |
Those results supported accelerated clinical interest in the program, but the subsequent Phase III trial produced no statistically persuasive benefit in the overall population. The trial enrolled about 500 patients with metastatic triple-negative breast cancer.
Reported Phase III outcomes included:
| Outcome | Iniparib arm | Control arm |
|---|---|---|
| Median progression-free survival | Approximately 4.1 months | Approximately 5.1 months |
| Median overall survival | Approximately 11.1 months | Approximately 11.8 months |
The Phase III results raised two issues. First, the efficacy signal from the Phase II trial did not replicate. Second, iniparib's mechanism was later questioned. The compound had been described as a PARP inhibitor, but subsequent laboratory work indicated that it did not inhibit PARP at clinically relevant concentrations in the same manner as established PARP inhibitors such as olaparib, rucaparib, niraparib, and talazoparib (Lord et al., 2013).
The failed Phase III result and uncertain mechanism eliminated the basis for an NDA strategy in breast cancer.
Is iniparib a PARP inhibitor?
Iniparib is generally not treated as a validated clinical PARP inhibitor.
Early development classified iniparib as a PARP inhibitor because of laboratory findings and its proposed use in combination with DNA-damaging chemotherapy. Later studies found that iniparib had weak or nonselective PARP inhibition at clinically relevant concentrations. Its activity may have involved other cellular targets, including protein modification and effects associated with reactive chemical groups, but no alternative mechanism produced a successful clinical development program.
This distinction matters commercially. The successful PARP inhibitor class has been built around defined pharmacology, biomarker strategies involving homologous recombination deficiency, and regulatory approvals in ovarian, breast, prostate, and pancreatic cancers. Iniparib has no approved indication and does not compete directly with the commercial PARP inhibitor market.
What patents protect iniparib?
No FDA-listed patent currently protects an approved iniparib product because iniparib was never approved in the United States.
The relevant intellectual-property categories would have included:
| Patent category | Potential scope | Commercial status |
|---|---|---|
| Composition of matter | Iniparib chemical structure and related compounds | Historical investigational protection |
| Pharmaceutical composition | Iniparib formulations and dosage forms | No FDA-approved product |
| Combination therapy | Iniparib with gemcitabine, carboplatin, or other chemotherapy | Historical method-of-use protection |
| Oncology treatment methods | Treatment of breast, ovarian, lung, or other cancers | No approved labeling |
| Manufacturing | Synthesis, intermediates, purification, and solid forms | Potential process barriers, not publicly established as active commercial barriers |
| Biomarker use | Patient selection based on DNA repair or tumor characteristics | No validated commercial indication |
The absence of an approved reference product is more important than any residual patent term. A patent may have existed or may remain technically unexpired, but it does not create a conventional generic-entry barrier when the sponsor has no approved product and no Orange Book-listed patents.
A complete freedom-to-operate or patent-term analysis would require claim-level review of historical BiPar and Sanofi filings in each relevant jurisdiction. The publicly established commercial record does not show a live, revenue-generating iniparib patent estate.
What is the Orange Book status of iniparib?
Iniparib has no Orange Book listing.
The FDA Orange Book lists approved drug products and, where applicable, associated patents and regulatory exclusivity. Because iniparib never received FDA approval, it has:
- No approved NDA.
- No Orange Book patent listing.
- No FDA pediatric exclusivity.
- No new chemical entity exclusivity.
- No approved labeling.
- No reference-listed drug status.
The drug therefore cannot be the subject of a conventional Abbreviated New Drug Application referencing an approved iniparib product.
When did iniparib lose exclusivity?
Iniparib did not lose market exclusivity through ordinary generic erosion. It failed before approval.
A conventional small-molecule lifecycle would involve composition-of-matter protection, regulatory exclusivity, Orange Book-listed patents, and eventual ANDA entry. Iniparib did not complete that lifecycle. Its commercial opportunity ended when the Phase III program failed and Sanofi discontinued development.
The practical exclusivity timeline is therefore:
| Exclusivity event | Status |
|---|---|
| FDA approval | Never occurred |
| NCE exclusivity | Never granted |
| Orange Book listing | None |
| Patent-protected commercial launch | None |
| Generic entry after approval | Not applicable |
| Current branded revenue | None established |
Were there Paragraph IV challenges to iniparib?
No material Paragraph IV challenge is established.
A Paragraph IV certification challenges the validity, enforceability, or infringement of an Orange Book-listed patent tied to an approved reference drug. Iniparib had no approved reference product and no Orange Book-listed patents. Accordingly, there was no conventional Paragraph IV dispute comparable to those involving approved oncology drugs.
Any later development of iniparib would likely require a sponsor to pursue a new application rather than rely on an existing FDA reference product.
What is the FDA regulatory status of iniparib?
Iniparib remains an unapproved investigational drug.
The FDA did not approve iniparib for triple-negative breast cancer, ovarian cancer, lung cancer, or any other indication. The drug did not obtain accelerated approval, traditional approval, or a marketed orphan-drug indication.
The failed Phase III study was a major regulatory barrier because the program lacked confirmatory evidence supporting the original efficacy signal. A new sponsor would likely need to establish a new benefit-risk profile through modern Phase I and Phase II development before initiating a registrational program.
Does iniparib have biosimilar or generic risk?
Iniparib has no biosimilar risk because it is a small molecule, not a biologic.
It also has no immediate generic risk in the conventional commercial sense. Generic manufacturers generally need an FDA-approved reference listed drug. Iniparib has no such product. A third party could theoretically develop and submit an independent full NDA for a new iniparib product, but that would require new clinical and regulatory investment.
The main risk is therefore not generic substitution. It is the possibility that another company develops a clinically differentiated DNA-damage or PARP-related therapy for the same patient population.
Which companies are challenging or competing with iniparib?
No company is currently challenging an iniparib product because no iniparib product is marketed.
The relevant competitive field is the approved PARP inhibitor market and emerging DNA-damage-response therapies.
| Company | Product or program | Relevance |
|---|---|---|
| AstraZeneca and Merck | Olaparib, Lynparza | Established PARP inhibitor with multiple oncology indications |
| Clovis Oncology, later related assets | Rucaparib, Rubraca | PARP inhibitor with ovarian and other oncology development history |
| GSK | Niraparib, Zejula | PARP inhibitor used in ovarian cancer |
| Pfizer | Talazoparib, Talzenna | Potent PARP inhibitor with breast and prostate cancer indications |
| Multiple biotechnology companies | ATR, WEE1, DNA-PK, POLQ, and other DDR programs | Potential competitors in synthetic-lethality oncology |
Iniparib's failure also affected the credibility of broad PARP-inhibitor claims. Later commercial success depended on more selective compounds, stronger pharmacology, and better biomarker-defined populations.
What is the market projection for iniparib?
The base-case market projection is zero.
| Projection period | Base-case revenue outlook | Rationale |
|---|---|---|
| 2024-2025 | $0 | No active commercial product or registration program |
| 2026-2027 | $0 | No disclosed restart or regulatory pathway |
| 2028-2030 | $0 | Requires new sponsor, new trials, and a successful NDA |
| Upside scenario | Unquantifiable | Depends on proof of a new mechanism and successful redevelopment |
There is no reliable basis for assigning iniparib a conventional peak-sales estimate. The original opportunity was tied mainly to metastatic triple-negative breast cancer, a high-unmet-need market in which other therapies have since advanced, including antibody-drug conjugates, immune checkpoint inhibitors, and newer targeted agents.
A redevelopment scenario would face several commercial constraints:
- The historical efficacy signal was inconsistent.
- The original PARP-inhibitor positioning was weakened by mechanistic data.
- The competitive market has more effective approved therapies.
- A new sponsor would need to fund clinical redevelopment without an established regulatory package.
- The compound lacks product, label, manufacturing, and physician-adoption infrastructure.
A repurposing program could create research value, but it should not be included in a base-case revenue forecast.
What manufacturing and intellectual-property barriers exist?
Iniparib is a synthetic small molecule, so manufacturing is less complex than for a biologic. The principal technical issues would involve:
- Reproducible synthesis of the active pharmaceutical ingredient.
- Control of reactive or chemically labile functional groups.
- Impurity characterization.
- Solid-state and formulation stability.
- Scalable production under current Good Manufacturing Practice standards.
- A validated analytical method suitable for clinical and commercial release.
Manufacturing alone is unlikely to create a durable market barrier. Any meaningful protection would depend on composition, formulation, process, or use claims that remain valid and commercially relevant. With no approved product, however, the commercial value of those barriers is limited.
How does iniparib compare with approved PARP inhibitors?
Iniparib differs from approved PARP inhibitors in clinical validation, mechanism, regulatory status, and market position.
| Attribute | Iniparib | Approved PARP inhibitors |
|---|---|---|
| FDA approval | None | Yes, for multiple products and indications |
| Clinical mechanism | Historically described as PARP inhibition; later questioned | Validated PARP inhibition and PARP trapping, depending on molecule |
| Biomarker strategy | Not commercially established | BRCA, homologous recombination, and disease-specific strategies |
| Orange Book status | None | Applicable to approved products |
| Commercial sales | None established | Established oncology revenue |
| Generic-entry framework | Not applicable | Patent and regulatory exclusivity dependent |
| Current development status | Discontinued | Commercial and, for some products, lifecycle development |
Key Takeaways
- Iniparib, or BSI-201, is a discontinued investigational oncology drug.
- Sanofi ended development after Phase III failed to confirm Phase II efficacy in metastatic triple-negative breast cancer.
- The compound was initially positioned as a PARP inhibitor, but later research questioned clinically relevant PARP inhibition.
- Iniparib was never approved by the FDA and has no Orange Book listing.
- No meaningful Paragraph IV, biosimilar, or conventional generic-entry issue exists.
- Any historical patents do not support an active commercial franchise without an approved product and renewed development.
- The 2024-2030 base-case market projection is zero.
- A commercial restart would require new sponsor ownership, new clinical evidence, and a differentiated mechanism or biomarker strategy.
FAQs About Iniparib
Is iniparib still being developed for triple-negative breast cancer?
No. Sanofi discontinued the program after the Phase III study failed to demonstrate a significant overall benefit.
Did iniparib receive FDA accelerated approval?
No. Iniparib never received accelerated approval or traditional FDA approval.
Is iniparib the same as olaparib?
No. Iniparib and olaparib are different chemical entities. Olaparib is an approved PARP inhibitor; iniparib is an unapproved and discontinued investigational compound.
Could iniparib be relaunched by another pharmaceutical company?
A relaunch would require a new sponsor to generate sufficient clinical and regulatory evidence. No established relaunch program has created a credible commercial forecast.
What was the largest original market opportunity for iniparib?
The principal opportunity was metastatic triple-negative breast cancer, particularly patients with limited treatment options. The opportunity declined after the Phase III failure and the emergence of newer targeted and immuno-oncology therapies.
References
-
FDA. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Food and Drug Administration.
-
FDA. (2024). Drugs@FDA: FDA-approved drugs database. U.S. Food and Drug Administration.
-
O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., et al. (2011). Iniparib plus chemotherapy in metastatic triple-negative breast cancer. New England Journal of Medicine, 364(3), 205-214.
-
O'Shaughnessy, J., Schwartzberg, L. S., Danso, M. A., Miller, K. D., Rugo, H. S., Neubauer, M., et al. (2014). Phase III study of iniparib in combination with gemcitabine and carboplatin in metastatic triple-negative breast cancer. Journal of Clinical Oncology, 32(34), 3840-3847.
-
Lord, C. J., Tutt, A. N. J., & Ashworth, A. (2013). Synthetic lethality and cancer therapy: Lessons learned from the development of PARP inhibitors. Annual Review of Medicine, 64, 161-175.
-
Sanofi. (2011). Sanofi development update for iniparib in metastatic triple-negative breast cancer. Sanofi press materials.
More… ↓
